QQQ   443.86 (-0.22%)
AAPL   171.16 (-1.24%)
MSFT   419.91 (-0.36%)
META   486.24 (-1.54%)
GOOGL   150.73 (-0.09%)
AMZN   179.96 (+0.07%)
TSLA   177.36 (-1.37%)
NVDA   905.83 (+0.37%)
NIO   4.56 (-2.36%)
AMD   180.53 (+0.52%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.18 (+0.92%)
MU   117.65 (-1.25%)
CGC   9.71 (+1.68%)
GE   174.83 (-2.94%)
DIS   122.49 (+1.25%)
AMC   3.68 (-15.21%)
PFE   28.02 (+0.86%)
PYPL   67.09 (+0.78%)
XOM   115.96 (+0.86%)
QQQ   443.86 (-0.22%)
AAPL   171.16 (-1.24%)
MSFT   419.91 (-0.36%)
META   486.24 (-1.54%)
GOOGL   150.73 (-0.09%)
AMZN   179.96 (+0.07%)
TSLA   177.36 (-1.37%)
NVDA   905.83 (+0.37%)
NIO   4.56 (-2.36%)
AMD   180.53 (+0.52%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.18 (+0.92%)
MU   117.65 (-1.25%)
CGC   9.71 (+1.68%)
GE   174.83 (-2.94%)
DIS   122.49 (+1.25%)
AMC   3.68 (-15.21%)
PFE   28.02 (+0.86%)
PYPL   67.09 (+0.78%)
XOM   115.96 (+0.86%)
QQQ   443.86 (-0.22%)
AAPL   171.16 (-1.24%)
MSFT   419.91 (-0.36%)
META   486.24 (-1.54%)
GOOGL   150.73 (-0.09%)
AMZN   179.96 (+0.07%)
TSLA   177.36 (-1.37%)
NVDA   905.83 (+0.37%)
NIO   4.56 (-2.36%)
AMD   180.53 (+0.52%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.18 (+0.92%)
MU   117.65 (-1.25%)
CGC   9.71 (+1.68%)
GE   174.83 (-2.94%)
DIS   122.49 (+1.25%)
AMC   3.68 (-15.21%)
PFE   28.02 (+0.86%)
PYPL   67.09 (+0.78%)
XOM   115.96 (+0.86%)
QQQ   443.86 (-0.22%)
AAPL   171.16 (-1.24%)
MSFT   419.91 (-0.36%)
META   486.24 (-1.54%)
GOOGL   150.73 (-0.09%)
AMZN   179.96 (+0.07%)
TSLA   177.36 (-1.37%)
NVDA   905.83 (+0.37%)
NIO   4.56 (-2.36%)
AMD   180.53 (+0.52%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.18 (+0.92%)
MU   117.65 (-1.25%)
CGC   9.71 (+1.68%)
GE   174.83 (-2.94%)
DIS   122.49 (+1.25%)
AMC   3.68 (-15.21%)
PFE   28.02 (+0.86%)
PYPL   67.09 (+0.78%)
XOM   115.96 (+0.86%)
NASDAQ:FLGT

Fulgent Genetics (FLGT) Stock Price, News & Analysis

$21.81
+0.12 (+0.55%)
(As of 01:21 PM ET)
Today's Range
$21.70
$22.16
50-Day Range
$21.55
$26.45
52-Week Range
$21.23
$44.09
Volume
69,905 shs
Average Volume
210,684 shs
Market Capitalization
$649.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00

Fulgent Genetics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
37.6% Upside
$30.00 Price Target
Short Interest
Healthy
3.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
-0.17mentions of Fulgent Genetics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.04) to ($1.66) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.27 out of 5 stars

Medical Sector

182nd out of 939 stocks

Medical Laboratories Industry

7th out of 20 stocks

FLGT stock logo

About Fulgent Genetics Stock (NASDAQ:FLGT)

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

FLGT Stock Price History

FLGT Stock News Headlines

Fulgent Genetics (NASDAQ:FLGT) Hits New 12-Month Low at $21.26
FLGT Apr 2024 20.000 call
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Q4 2023 Fulgent Genetics Inc Earnings Call
A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
Here's what to expect from Fulgent Genetics's earnings report
FLGT Mar 2024 30.000 call
FLGT Mar 2024 35.000 put
Following Up On Fulgent Genetics
Q3 2023 Fulgent Genetics Inc Earnings Call
Fulgent Genetics Reports Loss In Q3 On Lower Revenue
See More Headlines
Receive FLGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/28/2024
Next Earnings (Estimated)
5/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:FLGT
Employees
1,184
Year Founded
2011

Price Target and Rating

Average Stock Price Target
$30.00
High Stock Price Target
$35.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+38.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-167,820,000.00
Pretax Margin
-60.19%

Debt

Sales & Book Value

Annual Sales
$289.21 million
Cash Flow
$3.18 per share
Book Value
$38.24 per share

Miscellaneous

Free Float
20,325,000
Market Cap
$645.93 million
Optionable
Optionable
Beta
1.45

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Ming Hsieh (Age 68)
    Chairman & CEO
    Comp: $1.66M
  • Mr. Jian Xie (Age 58)
    COO & President
    Comp: $755.73k
  • Mr. Paul  KimMr. Paul Kim (Age 57)
    Chief Financial Officer
    Comp: $757.59k
  • Dr. Hanlin Gao D.A.B.M.G. (Age 57)
    FACMG, M.D., Ph.D., Chief Scientific Officer & Laboratory Director
    Comp: $630.61k
  • Ms. Natalie Prescott
    General Counsel & Chief Privacy Officer
  • Ms. Doreen Ng
    VP of Operations & Compliance and GM of Houston Office
  • Mr. Jakub Sram
    Vice President of Business Development & Sales
  • Ms. Ellen Tsui
    Vice President of Human Resources
  • Mr. Brandon Perthuis
    Chief Commercial Officer
  • Dr. Lawrence M. Weiss M.D. (Age 67)
    Chief Medical Officer

FLGT Stock Analysis - Frequently Asked Questions

Should I buy or sell Fulgent Genetics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" FLGT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FLGT, but not buy additional shares or sell existing shares.
View FLGT analyst ratings
or view top-rated stocks.

What is Fulgent Genetics' stock price target for 2024?

2 brokers have issued 1-year price targets for Fulgent Genetics' stock. Their FLGT share price targets range from $25.00 to $35.00. On average, they expect the company's stock price to reach $30.00 in the next twelve months. This suggests a possible upside of 37.6% from the stock's current price.
View analysts price targets for FLGT
or view top-rated stocks among Wall Street analysts.

How have FLGT shares performed in 2024?

Fulgent Genetics' stock was trading at $28.91 at the beginning of the year. Since then, FLGT stock has decreased by 24.6% and is now trading at $21.81.
View the best growth stocks for 2024 here
.

Are investors shorting Fulgent Genetics?

Fulgent Genetics saw a increase in short interest in March. As of March 15th, there was short interest totaling 611,200 shares, an increase of 22.6% from the February 29th total of 498,400 shares. Based on an average daily trading volume, of 208,900 shares, the days-to-cover ratio is currently 2.9 days. Currently, 3.2% of the shares of the stock are short sold.
View Fulgent Genetics' Short Interest
.

When is Fulgent Genetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our FLGT earnings forecast
.

How were Fulgent Genetics' earnings last quarter?

Fulgent Genetics, Inc. (NASDAQ:FLGT) announced its earnings results on Wednesday, February, 28th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.61. The company earned $70.51 million during the quarter, compared to analysts' expectations of $67.14 million. Fulgent Genetics had a negative net margin of 58.03% and a negative trailing twelve-month return on equity of 3.04%.

What guidance has Fulgent Genetics issued on next quarter's earnings?

Fulgent Genetics updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of -1.050--1.050 for the period, compared to the consensus EPS estimate of -0.950. The company issued revenue guidance of $280.0 million-$280.0 million, compared to the consensus revenue estimate of $294.2 million.

What other stocks do shareholders of Fulgent Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Block (SQ), JD.com (JD), Marvell Technology (MRVL), Teladoc Health (TDOC) and Editas Medicine (EDIT).

When did Fulgent Genetics IPO?

Fulgent Genetics (FLGT) raised $60 million in an IPO on Thursday, September 29th 2016. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Credit Suisse and Piper Jaffray acted as the underwriters for the IPO and Raymond James and BTIG were co-managers.

Who are Fulgent Genetics' major shareholders?

Fulgent Genetics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (4.88%), Vanguard Group Inc. (4.78%), Vanguard Group Inc. (4.75%), Park West Asset Management LLC (1.43%), Nuveen Asset Management LLC (0.93%) and Charles Schwab Investment Management Inc. (0.90%). Insiders that own company stock include Hanlin Gao, Jian Xie, John C Bolger, Paul Kim and X Cycle LP Tcv.
View institutional ownership trends
.

How do I buy shares of Fulgent Genetics?

Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Fulgent Genetics have any subsidiaries?
The following companies are subsidiares of Fulgent Genetics: CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, Fulgent Therapeutics LLC, and Inform Diagnostics.
Read More
This page (NASDAQ:FLGT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners